Tuesday, November 05, 2024 6:43:54 PM
thanks
I agree with you on BLA because of the absence of individual patient data.
I do not think they will be in any position to start any other trial Direct, pediatric, or another cancer indication without a large financial injection.
How on earth they will be able to sell support 500 to 1000 batches the 12 months after UK approval is a big other question mark to me. A sales department is an investment for which they hardly have any cash. NICE is also a question mark since they could lose approval if they keep refusing to engage with, with an economic model for which they also need cash.
I believe that right after UK approval they will submit an MAA with the EMA and will get approval there soon after (maybe even 6 months) because of the cooperation between the MHRA and the EMA.
I think NWBO will after UK approval be at a crossroads either they will team up with a large pharma for a good financial injection and get things done at double speeds or they will linger stock price/market cap will go back to where we are today and they will not get much done.
So al in all I think Powers will have to make a hard choice accept a deal with big pharma on perhaps less favorable terms or perish.
I agree with you on BLA because of the absence of individual patient data.
I do not think they will be in any position to start any other trial Direct, pediatric, or another cancer indication without a large financial injection.
How on earth they will be able to sell support 500 to 1000 batches the 12 months after UK approval is a big other question mark to me. A sales department is an investment for which they hardly have any cash. NICE is also a question mark since they could lose approval if they keep refusing to engage with, with an economic model for which they also need cash.
I believe that right after UK approval they will submit an MAA with the EMA and will get approval there soon after (maybe even 6 months) because of the cooperation between the MHRA and the EMA.
I think NWBO will after UK approval be at a crossroads either they will team up with a large pharma for a good financial injection and get things done at double speeds or they will linger stock price/market cap will go back to where we are today and they will not get much done.
So al in all I think Powers will have to make a hard choice accept a deal with big pharma on perhaps less favorable terms or perish.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
